Two allosteric inhibitors are better then one!

AZD-6244 is Array’s MEK inhibitor [ARRY-886] which failed a solo ph2 endpoint not too long ago.

MK-2206 is Merck’s ph1 AKT inhibitor
| CARVIEW |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
Posted by kinasepro on June 2, 2009
Two allosteric inhibitors are better then one!

AZD-6244 is Array’s MEK inhibitor [ARRY-886] which failed a solo ph2 endpoint not too long ago.

MK-2206 is Merck’s ph1 AKT inhibitor
Posted in Array, Astra, Merck & Co. | Leave a Comment »
Posted by kinasepro on October 23, 2008
aka ARRY-424704 / AZD-8330 is the Array / Astra Mek Ph1 backup to ARRY-886 / AZD-6244 which was put in a holding pattern when it didn’t meet a ph2 endpoint. The pictured strucuture is ‘Mek Inhibitor II’ in the combination app WO/2008/125820:
Posted in Array, Astra, MEK | 2 Comments »
Posted by kinasepro on November 20, 2007
…to evaluate the efficacy of ARRY-797 in the management of postoperative dental pain…
(C(N)=O)CCC3CC3)=O)=C2)OC4=C(C=C(C=C4)F)F)C](https://i0.wp.com/img201.imageshack.us/img201/7457/arrayil8.jpg)
still no structure disclosed afaik, but likely a cousin of the above.
Posted in Array, p38 | 5 Comments »
Posted by kinasepro on September 25, 2007
…Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets…
Looks like unpartnerds include: KSP, P38, P38/tie2, Erbb1-2, RAF, TLR’s, etc…
Posted in Array, Celgene, Deals | Leave a Comment »
Posted by kinasepro on September 19, 2007
It’s an Array / Genentech c-Met app:
[C@H]3NC1=NNC2=C1C(OC4=CC=C(N([H])C(C5=CC=NN(C6=CC=C(F)C=C6)C5=O)=O)C=C4F)=CC=N2](https://i0.wp.com/img514.imageshack.us/img514/879/agya5.jpg)
Posted in Array, c-Met, Genentech | 8 Comments »
Posted by kinasepro on August 4, 2007
IND: in the books, Market: not impressed. If you’ve been paying attention you already noticed Array’s got ‘n’ ErbB series published 5/24: WO/2007/059257

ARRY-380, a selective, orally-active ErbB-2 inhibitor, has shown efficacy and is well-tolerated in preclinical models of human cancer.
Posted in Array, EGF | 1 Comment »
Posted by kinasepro on March 14, 2007
Wo/2007/027855 Matches their earlier Raf kinase application – this time with furanopyridines and some new tail pieces.

Posted in Array, RAF | 1 Comment »
Posted by kinasepro on February 22, 2007
I haven’t read it, but Cephalon’s got an Expert Opinion on the Array Biopharma / AstraZeneca’s Trk-A applications: WO06087538, WO06087530
C=C1)N2C=NC3=CC(Cl)=C(NC4=NNC(C5CC5)=C4)N=C32 C[C@@H](NC1=NC2=C(N=C([H])N2C3=NNC(C4CC4)=C3)C=N1)C5=CC=C(F)C=C5](https://i0.wp.com/img337.imageshack.us/img337/3571/az1pt6.jpg)
In the series there’s also: WO/2006/082392
C=C4)C](https://i0.wp.com/img480.imageshack.us/img480/7938/az2ml5.jpg)
Cephalon’s got a staurosporine analog CEP-701 that hits the kinome, err I mean Vegfr-2, FLT-3, Trk-A and JAK-2 in ph3 trials for AML.
Bonus Link: Multi-Targeted Therapy = nice site.
Posted in Array, Astra, Trk | Leave a Comment »
Posted by kinasepro on December 29, 2006
Wull Duh? But in this case it’s a webcast on medchem from some mostly non-chemists: David Snitman, Paul Goddard, Arthur Sands, and Jim Mahoney of Array, ARYx, Lexicon, and Surface Logix respectively.
Posted in Array, biotech, Lexicon, MEK | 5 Comments »